Investigating immune interactions in Alzheimer's disease and testing a new immunotherapy
Official title: Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy
Funded at Methodist Hospital Research Institute · NIH-11004684 · Data updated 2026-11-12
This study is looking at how inflammation might impact Alzheimer's disease by checking certain markers in your blood and spinal fluid, and it will also test a new low-dose treatment to see if it helps improve brain function and memory over 22 weeks for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $592,201 |
| NIH project number | 5R01AG077685-03 |
| Project ID | NIH-11004684 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are experiencing cognitive decline.
✕Less likely to help
Patients with other forms of dementia or those not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on understanding how inflammation affects Alzheimer's disease by measuring specific inflammation biomarkers in blood and cerebrospinal fluid. It aims to compare these biomarkers with brain activity related to inflammation using advanced imaging techniques. Additionally, the study will evaluate the effects of a novel low-dose immunotherapy, interleukin-2, over a 22-week period on these biomarkers in individuals with Alzheimer's disease. Participants will also undergo cognitive assessments to determine any improvements in their condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve cognitive function and slow the progression of Alzheimer's disease.
How similar studies have gone: Previous studies have shown promising results with immunotherapy approaches in Alzheimer's disease, indicating potential for success in this novel investigation.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Faridar, Alireza — Methodist Hospital Research Institute
- Study coordinator: Faridar, Alireza
Related research
Other NIH-funded projects on the same topics.
-
Immune cell aging and metabolism as a target for Alzheimer's treatment
This work looks at whether aging immune cells called T cells and their fat-related metabolism drive Alzheimer's and whether changing them could point to new treatments for people with AD.
-
Blood–brain barrier and tiny brain changes linked to side effects and outcomes of anti‑amyloid treatment for Alzheimer’s
This project will look at blood–brain barrier health and small brain changes to help predict side effects and treatment outcomes for people with Alzheimer’s disease.
-
Understanding how aging immune cells contribute to Alzheimer's disease
This study is looking at how aging immune cells called T cells might affect the buildup of harmful proteins in Alzheimer's disease, with the hope of finding new ways to help people with this condition.
-
Investigating brain changes and risks from new Alzheimer's treatments
This study is looking at how new treatments for Alzheimer's disease might affect the brain, especially any potential risks, so we can better understand how to keep patients safe while using these therapies.
-
New treatment targeting tau protein for Alzheimer's disease
This study is working on a new treatment for Alzheimer's disease that uses special antibodies to target a harmful protein in the brain, with the hope of helping people with Alzheimer's feel better and protect their brain health.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.